文献速递神经肿瘤

垂体特异性转录因子引入后静默型促肾上腺皮质激素腺瘤的临床影像学分析

A clinicoradiological analysis of silent corticotroph adenomas after the introduction of pituitary-specific transcription factors.
PubMed 文献 · Acta Neurochir (Wien) · 2021-06-28

该单中心回顾性研究依据WHO 2017标准纳入62例静默型促肾上腺皮质激素腺瘤(SCA)与238例其他无功能腺瘤(ONA),比较临床影像特征及术后进展/复发。SCA患者更年轻、肿瘤更大且更具侵袭性,术后复发或进展率更高(48.7% vs 15.7%,p<0.001);对术后残留的SCA,早期辅助放疗可获得与ONA相当的结局。

要点

  • SCA较ONA更年轻、肿瘤更大且更具侵袭性。
  • SCA术后复发或进展率显著高于ONA。
  • 术后残留SCA早期辅助放疗结局与ONA相当。

核心结论

  • SCA是无功能垂体腺瘤中更具侵袭性的亚型,肿瘤更大、更易侵袭、次全切除后复发更频繁。
  • 应尽可能争取全切除,当残留肿瘤再次手术困难时推荐早期辅助放疗。

研究设计与样本

  • 回顾性单中心研究,依据WHO 2017标准(纳入转录因子分析)纳入62例SCA与238例ONA,共300例无功能腺瘤。
  • 对52例SCA与205例ONA的连续随访影像分析次全切除后进展(伴或不伴放疗)或全切除后复发。
  • 采用Kaplan-Meier分析复发或进展,评估SCA是否需要区别于ONA的放疗策略。

主要发现

  • SCA患者发病年龄低于ONA(43.9岁 vs 48.2岁,p=0.014)。
  • SCA肿瘤体积大于ONA(14.9 cc vs 9.7 cc,p=0.006),侵袭性比例更高(61.2% vs 45.8%,p=0.021)。
  • SCA术后复发或进展率高于ONA(48.7% vs 15.7%,p<0.001),无事件生存显著更差(Log rank检验 p<0.001)。
  • 多因素分析显示男性(HR: 2.217;p=0.017)、MIB指数≥3%(HR: 2.116;p=0.012)及SCA病理(HR: 3.787;p<0.001)为复发预测因素。

关键数值与推荐

  • SCA诊断依据WHO 2017标准,纳入垂体特异性转录因子分析。
  • 对术后残留肿瘤的SCA,早期辅助放疗可获得与ONA相当的结局。

临床怎么用

  • 对SCA应尽可能实现全切除。
  • 术后残留且再次手术困难时,推荐早期辅助放疗。
  • 男性、MIB指数≥3%及SCA病理提示复发风险较高,需加强随访。

局限性

  • 回顾性单中心研究设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Silent corticotroph adenomas (SCAs) are a rare subtype of non-functional pituitary adenoma. While it has been suggested that they are more aggressive and recur more frequently following excision, there is limited literature on the optimum treatment strategy for these tumors, especially regarding the role of radiation therapy in incompletely resected tumors. METHOD: We assimilated data from 62 SCAs and 238 other non-functional adenomas (ONAs), defined according to the WHO 2017 criteria that incorporates transcription factor analysis. We compared their clinicoradiological characteristics, such as hormonal levels, tumor configuration, size, and invasiveness. For 52 SCAs and 205 ONAs with serial follow-up imaging, we studied outcomes for progression after subtotal resection with or without radiation therapy or recurrence after gross total resection. Kaplan Meier analysis for recurrence or progression was used to determine the need for a differential treatment strategy for SCAs compared with other non-functional adenomas specifically concerning the role of radiotherapy. RESULTS: Patients with SCAs present at a younger age than ONAs (43.9 years vs. 48.2 years, p = 0.014), with larger (14.9 cc vs. 9.7 cc, p = 0.006) and more invasive adenomas (61.2% vs. 45.8%, p = 0.021). Overall, SCAs are more likely to recur or progress (48.7 vs. 15.7%, p < 0.001) following excision than ONAs, with significantly poorer event-free survival (Log rank test p < 0.001). Early adjuvant radiotherapy provides favorable outcomes among SCAs with postoperative residual tumor, on par with ONAs. Multivariate analysis identified male gender (HR: 2.217; p = 0.017), MIB index ≥ 3% (HR: 2.116; p = 0.012), and SCA tumor pathology (HR: 3.787; p < 0.001) as factors predicting recurrence. CONCLUSIONS: Based on the results of this retrospective, single-center review of 300 non-functional adenomas, we conclude that silent corticotroph adenomas are an aggressive subtype of non-functional pituitary adenomas that are larger, more likely to be invasive, and tend to recur more frequently after a subtotal excision compared with other non-functional adenomas. A gross total resection must be attempted whenever possible and earlier adjuvant radiation is recommended when re-surgery for residual tumor is difficult.

来源:Acta Neurochir (Wien),查看原文。版权归原作者所有。

引用

  1. Goyal-Honavar A, Sarkar S, Asha HS, et al. A clinicoradiological analysis of silent corticotroph adenomas after the introduction of pituitary-specific transcription factors. Acta Neurochir (Wien). 2021. PMID: 34181087. doi:10.1007/s00701-021-04911-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。